狂犬病暴露前预防在人类中引发持久免疫
本研究评估了一组狂犬病疫苗接种者长达二十年的狂犬病特异性中和抗体反应,分析了初次接种和加强接种后的抗体应答及抗体消退情况,并评价了性别、接种年龄、疫苗生产商和接种间隔的影响。数据证实狂犬病疫苗接种可引发中和抗体应答,且无需额外加强接种即可在数年内保持可检测水平。初次接种和加强接种后的抗体应答均显著受受试者性别影响(分别为p=0.002和0.03)。
要点
- 狂犬病疫苗接种可引发中和抗体应答,无需额外加强接种即可在数年内保持可检测水平。
- 初次接种和加强接种后的抗体应答均显著受性别影响(p=0.002和0.03)。
- 初次接种后抗体滴度随时间的总体下降率为时间每变化2倍降低37%,加强接种后为降低27%。
核心结论
- 狂犬病疫苗接种可引发中和抗体应答,无需额外加强接种即可在数年内保持可检测水平。
研究设计与样本
- 本研究评估了一组狂犬病疫苗接种者长达二十年的狂犬病特异性中和抗体反应。
主要发现
- 初次接种和加强接种后的抗体应答均显著受受试者性别影响(p=0.002和0.03)。
- 初次接种后,在少量受试者(n=5)中观察到2006年前生产的某一种疫苗的中和抗体滴度显著更高(p<0.001)。
- 所有个体抗体滴度总体下降,初次接种后和加强接种后时间每变化2倍分别降低37%和27%。
- 初次接种程序后,年龄较大组的抗体滴度下降显著更快(p=0.012)。
- 初次接种程序后,抗体滴度下降速率也显著受疫苗生产商影响(p<0.001)。
临床怎么用
- 中和抗体滴度下降的评估为加强接种的最适时机提供了见解,并使得能够从接种后抗体滴度预测长期滴度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the availability of safe and effective human vaccines, rabies remains a global threat, with an estimated 60,000 human deaths annually attributed to rabies. Pre-exposure prophylaxis against rabies infection is recommended for travelers to countries where rabies is endemic, and also for those with a higher risk of exposure. In this study, the rabies-specific neutralising antibody responses in a cohort of rabies-vaccinated recipients over a period of twenty years have been assessed. In particular, the antibody response to primary vaccinations and boosters, and the waning of antibody post primary vaccination and post booster were investigated. The significance of gender, age at vaccination, vaccine manufacturer and vaccination intervals were also evaluated. These data confirm that rabies vaccination can elicit a neutralising antibody response that can remain at detectable levels for a number of years, without additional booster vaccinations. The antibody response following both primary vaccination and booster was significantly influenced by the gender of the subject (p=0.002 and 0.03 respectively), with supportive data that suggests an effect by the make of vaccine administered following primary vaccination, with significantly higher VNA titres observed for one vaccine manufactured prior to 2006 (p<0.001) in a small subset of recipients (n=5). Additionally, the decay rate was demonstrated through the overall decline in antibody titre for all individuals, which was a 37% and 27% reduction per 2-fold change in time following primary and booster vaccination respectively. Individuals within older age groups demonstrated a significantly faster decline in antibody titre following the primary vaccination course (p=0.012). Rate of decline in antibody titre was also significantly influenced by the vaccine make following primary course (p<0.001). The assessment of neutralising antibody titre decline has also provided an insight into the most appropriate timing for booster administration, and enabled the prediction of long term titres from post-vaccination antibody titres.
引用
- Mansfield KL, Andrews N, Goharriz H, et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine. 2016. PMID: 27997343. doi:10.1016/j.vaccine.2016.09.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。